[Letter: Inhibitor of H 2 histamine receptors and the Zollinger-Ellison syndrome].
D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000209:etiology; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D005755:Gastrins / Q000037:antagonists & inhibitors* / Q000097:blood; D005767:Gastrointestinal Diseases / Q000175:diagnosis / Q000188:drug therapy*; D006634:Histamine H1 Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D011955:Receptors, Drug / Q000187:drug effects; D013440:Sulfides / Q000494:pharmacology; D013577:Syndrome; D013890:Thiourea / Q000031:analogs & derivatives* / Q000494:pharmacology
D005755:Gastrins; D006634:Histamine H1 Antagonists; D007093:Imidazoles; D011955:Receptors, Drug; D013440:Sulfides; D013890:Thiourea
Inhibiteur des récepteurs H 2 à l'histamine et syndrome de Zollinger-Ellison